NCT00869999View on ClinicalTrials.gov

Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

Everolimus

Taken orally once daily in the morning

DRUG

rituximab

Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconsess Medical Center, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Novartis

INDUSTRY

lead

Massachusetts General Hospital

OTHER